Share on StockTwits

Cytosorbents Corp (NASDAQ:CTSO) Director Al Kraus sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $0.27, for a total value of $27,000.00. Following the completion of the transaction, the director now directly owns 1,393,631 shares in the company, valued at approximately $376,280. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at HC Wainwright initiated coverage on shares of Cytosorbents Corp in a research note on Monday. They set a “buy” rating and a $1.00 price target on the stock.

Shares of Cytosorbents Corp (NASDAQ:CTSO) traded up 1.06% on Tuesday, hitting $0.2678. The stock had a trading volume of 456,019 shares. Cytosorbents Corp has a 52 week low of $0.09 and a 52 week high of $0.35. The stock’s 50-day moving average is $0.25 and its 200-day moving average is $0.24. The company’s market cap is $80.1 million.

Cytosorbents Corp (NASDAQ:CTSO) last released its earnings data on Tuesday, August 12th. The company reported ($0.01) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.01). On average, analysts predict that Cytosorbents Corp will post $-0.03 earnings per share for the current fiscal year.

CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.